Skip to main content
Onco-Innovations logo

Onco-Innovations — Investor Relations & Filings

Ticker · ONCO ISIN · CA68237C1059 LEI · 529900BRM2J6NM6CYX21 NEO Professional, scientific and technical activities
Open in API
Filings indexed 86 across all filing types
Latest filing 2026-04-24 Regulatory Filings
Country CA Canada
Listing NEO ONCO

About Onco-Innovations

https://oncoinnovations.com/

Onco-Innovations is a biotechnology company specializing in oncology research and the development of cutting-edge therapies to prevent and treat cancer. The company focuses on next-generation treatments, particularly those targeting solid tumors, leveraging an exclusive global license for patented technology. To advance precision oncology, Onco-Innovations utilizes the SynoGraph™ AI platform (acquired through Inka Health) to accelerate patient identification, optimize treatment planning, and streamline its drug development pipeline.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 82% confidence The document is a CFO’s statutory certification under Canadian NI 52-109 for the issuer’s annual filings (AIF, financial statements, MD&A) for the year ended Dec. 31, 2025. It is a regulatory attestation form (Form 52-109FV1), not the annual report itself, an earnings release, or any other specific category. It does not announce publication of a report but is a mandatory regulatory filing. Therefore it falls under the general Regulatory Filings category (RNS).
2026-04-24 English
News release - English.pdf
Regulatory Filings Classification · 45% confidence The document is a corporate news release announcing technical progress on polymer testing for a drug candidate, not financial results, voting, management changes, or regulatory submissions like 10-K or IR. It is neither an earnings release nor a detailed report, but a general press announcement. It does not fit any specialized category, so it falls under the fallback Regulatory Filings (RNS) for miscellaneous corporate announcements.
2026-04-24 English
News release - English.pdf
Regulatory Filings Classification · 30% confidence The document is a corporate press/news release announcing completion of an R&D milestone (analytical method development) for a pharmaceutical program. It does not present financial results (excluding earnings), governance changes, capital actions, or other specific report types, nor is it a notice of an upcoming report. It is a general corporate announcement and best fits the fallback category for miscellaneous regulatory or press filings.
2026-04-22 English
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a corporate news release announcing completion of an analytical method development milestone for a drug program. It contains no financial results, no shareholder vote or proxy materials, no regulatory form filings, no management changes, no dividends, etc. It does not present an investor presentation, report attachment, or any fitting specialized category. Therefore, it falls into the general "Regulatory Filings" fallback category (RNS).
2026-04-22 English
Material change report - English.pdf
Board/Management Information Classification · 100% confidence The document is a Form 51-102F3 Material Change Report filed by Onco-Innovations Limited. It announces the appointments of two senior executives (Chief Medical Officer and Chief of Research and Development) and the issuance of restricted share units to directors, officers, consultants, and service providers. The document includes detailed descriptions of the appointments and the company's strategic direction. The key focus is on changes in senior management and related equity grants. There is no financial data or quarterly/annual report content, nor is it a transcript, proxy, or dividend notice. The document fits the definition of Board/Management Information (MANG) as it announces changes in the company's senior management and related equity incentives.
2026-04-20 English
Material change report - English.pdf
Board/Management Information Classification · 95% confidence The document is titled 'FORM 51-102F3 MATERIAL CHANGE REPORT' and details the appointment of new executives (Chief Medical Officer and Chief of Research and Development) along with issuance of restricted share units. It includes a news release about these appointments and the company's strategic direction. The content focuses on changes in senior management and related equity grants. There are no financial statements or detailed financial performance data, so it is not an Annual Report, Interim Report, or Earnings Release. The document is not a proxy solicitation, voting results, or a regulatory certification. The primary focus is on announcing changes in the company's board or senior management. Therefore, the document fits best under the category 'Board/Management Information (MANG)'. The document length (10,405 characters) supports it being a full announcement rather than a brief notice or report publication announcement. Confidence is high given the clear focus on management appointments and equity grants to insiders.
2026-04-20 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.